Saatja: Tatiana Bronzova <
[email protected]>
Saadetud: 11.05.2020 12:16
Adressaat: Heli Laarmann <
[email protected]>
Koopia: SM Info <
[email protected]>; <
[email protected]>;
<
[email protected]>; <
[email protected]>;
<
[email protected]>
Teema: Mass Testing for Coronavirus - Digital Platform Solution
Dear Mrs.Laarmann,
Regarding positively changed status of Corona virus epidemic in Estonia
and in Finland and Estonian Governments
decision (on 9th of April) to start mass testing of people for
Coronavirus based on suitable antibody tests, we contacted
on the 28th of April AS Tallink Grupps Mr. Joonas Joost (Advisor for
Management) and their Team for New Safety Measures
with our suggestion (see email below) and notice of desire to co-operate
with them.
Because we observed from the news that Estonian Government has made a
decision (on 8th of May) that restrictions for border
crossings between Estonia and Finland will be eased and voluntary Corona
testing - arranged by the Ministry of Social Affairs-
will be carried out on board of ships travelling between Finland and
Estonia from May 14 to 19, we dare to approach now also
you with our previous suggestion.
We really believe that our Digital COVID-19 Rapid Tests and Diagnostic
Platform could be a part of modern solution for mass
testing of Corona virus. Naturally it is matched to use our present
Lateral Flow Test kits but its software algorithms are easily
adaptable to utilize images from any Lateral Flow Test kits. We would
like to underline that the Analytics Secure Cloud
(Amazon AWS) is easy to connect to Third-Party System like a local EHR
(Electronic Health Record). Our technology is
used already on 4 continents - it is approved by US FDA, Chinese FDA, and
it is CE marked.
Thus, we would like to suggest, would it be possible for you to consider
our Digital COVID-19 Rapid Tests and Diagnostic
Platform as an alternative for mass testing of COVID-19. We would be
pleased to deliver for you more information about our product.
We can deliver our test kit samples for you for analysis and we can
organize a Skype meeting with you and our Team of specialists.
If you see our contribution valuable for Estonia, we are happy to co-
operate with you.
Best regards
Board member Tatiana Bronzova
Board member Freddy E.Descamps MD, MPH, FACPM
Consultant Tapio Mäenpää D.Sc.
T +372 5299742 | M +37254005045 |
Westline Medicare OÜ | Pärnu mnt 139d,
Tallinn, Harju maakond, 11317
Estonia , Reg.N: 12345460 VAT:
EE101593173, IBAN:EE97 2200 2210 5595 6344 , SWIFT/BIC: HABAEE2X
Swedbank
AS Liivalaia 8,15040 Tallinn Estonia ,
email:
Îò: Tatiana Bronzova <
[email protected]>Äàòà: âòîðíèê,
28 àïðåëÿ 2020 ã., 14:48Êîìó: <
[email protected]>Êîïèÿ:
<
[email protected]>Òåìà: Cooperation A Way to Return to Normal
Business after Corona peak
Dear Sir/Madam,
Does your company have a strategy how to proceed and return to normal
business when the Corona restrictions are
gradually phased out, as is currently being planned e.g. in Finland. Have
you considered with your stakeholders what
ways to move into normal business. Have you considered proactive measures
that would support e.g. Finlands so-called
hybrid strategy for Corona or Estonian's mass tests option to determine
latency of COVID-19.
We would like to suggest, weather a strategy similar to the Emirates
Airlines has applied to its business, could be possible for you
and your stakeholders: "Emirates Airlines has begun conducting rapid
coronavirus tests on passengers before they board a flight."
A modern, proven technology to support this kind of strategy exists. We
would be pleased to present to you and your stakeholders
Rapid Coronavirus Test technology that fulfills these requirements. We
can offer two new technologies:
Digital COVID-19 Rapid Tests and Diagnostic Platform
We would like to introduce to you our partners developed mobile
diagnostics Point of Care platform which can detect IgM and IgG
antibodies and provide a digital analysis.
It integrates diagnostics, mobile technology and cloud computing into one
platform. Actually it turns a smartphone into a virtual lab where the
results
are displayed, offering faster, easier, and precise diagnostics, enabling
quick action and treatment.In addition, the cost of the test is
significantly low as compared
to PCR test.The biggest advantage is that it creates a digitised
diagnostic data with geographical mapping that can help monitor and
control outbreaks.
Digital test kit works in the same way blood sugar is tested by using a
pinprick on patients thumbs. The results can be obtained within minutes.
The rapid test kits, with lgM&lgG sensitivity of 97.6% and specificity
100%, can help save time and reduce direct contact as one counter set up
at a Point of Care location can test hundreds of patients.
Test is done in three steps
1. Take a test - Nurse or doctor performs the diagnostic test with a test
kit
2. Read the test - Scanned in a mobile phone using Immediate Diagnostics
and Analytics application
3. Store result - Immediate Diagnostics and Analytics Secure Cloud checks
the result immediately for diagnosis
After the test is conducted, the complete data with patient information
and GPS location is automatically sent to the Immediate Diagnostics and
Analytics Secure
Cloud and is available for the health care professionals and
stakeholders.The experts can then accordingly guide the person on the
ground. If it is negative, no action is required.
If it is positive, guide them to the treatment services. If there is some
error, test again.
Benefits of the Digital COVID-19 Rapid Test
* It enables faster, convenient, precise and cost-effective diagnostics
combining mobile technology and cloud computing.
* Lateral flow test quality control and quality assurance.
* As compared to PCR tests, the digital test reduces both human error
and technology gaps.
* It saves time and cost as the results are recorded digitally and
uploaded to the cloud platform instead of manual reports and a visit to
labs.
* Seamless data management integration into client / stakeholder
information systems.
* Reduce direct contact and virus exposure, as patients do not need to
go to hospitals or clinics.
* Test results obtained in minutes whereas the PCR tests results may
take 24 to 48 hours.
* It can help generate and divide data by age, gender and locations,
publishing visual reports and producing heat maps of infections.
* Disease surveillance and real time epidemic alerts via interactive
mapping.
Westline Medicare OÜ represents new rapid COVID-19 test method which can
identify the COVID-19 strain.
This new method is developed by Randox Biosciences and Bosch Healthcare
Solutions.
Westline Medicare OÜ is a distributor Randox Biosciences on the
territory in Estonia.
The new test will utilise Randox Biochip Technology, with results
available from the Vivalytic - the universal diagnostic platform for
point of care within 2 1/2 hours.
The Randox test is able to differentiate between the 10 following viral
respiratory pathogens, this screening is unique to Randox and will save
the laboratory both time and money running many separate PCR tests. The
WHO recommends testing for multiple respiratory pathogens as co-
infections can occur.
Our testing methods offered on both the vivalytic and evidence
investigator use multiplex PCR followed by detection using our unique
biochip technology. The biochip array technology allows simultaneous
detection of multiple analytes from a single sample. Each biochip has
duplicate discrete testing regions for the 10 viral respiratory pathogens
as internal QC to prevent reporting of false positive results. The
biochip detection is based on chemiluminescence, which is very sensitive.
Currently in the hospital, they are conducting RT-PCR for the SARS-Cov-19
E gene to screen followed by confirmation RT-PCR of the RDRP gene. This
is a very time consuming process. The Randox panel allows one test to
cover both the screening and confirmation PCR for SARS-Cov-19, as well as
9 other viral pathogens including other Corona virus subtypes which all
present the same symptoms. The updated WHO testing recommends testing for
multiple pathogens as co-infections are very common.
Analysers for IVD:
Vivalytic:
* One patient sample in per cartridge. Each cartridge can test for 10
viral pathogens including the COVID-19, giving results in 2 1/2 hours.
* This machine is designed as a POC machine and can be used outside the
laboratory by non-laboratory trained staff. Eg. Can be used on cruise
ship, nurse in GP office, airport etc.
Please find attached a brochure of this new testing method.
If you have anything to ask - we are pleased to answer you.
Best regards
Board member Tatiana Bronzova
Board member Freddy E.Descamps MD, MPH, FACPM
Consultant Tapio Mäenpää D.Sc.
T | M |
Westline Medicare OÜ | Pärnu mnt 139d,
Tallinn, Harju maakond, 11317 Estonia
Reg.N: VAT: EE101593173
IBAN:EE97 2200 2210 5595 6344 , SWIFT/BIC: HABAEE2X Swedbank
email:
Why Do We Need Antibody Tests for COVID-19
Diagnosing viral infections currently relies on two major methodologies: Reverse Transcription
Quantitative Polymerase Chain Reaction (RT-qPCR) and serological immunoassays that detect
viral-specific antibodies (IgM and IgG) or antigens.
Although, RT-qPCR is a highly sensitive test for SARS-CoV-2 (the virus that causes COVID-19)
it has its limitations. RT-qPCR requires high-quality nasopharyngeal swabs containing sufficient
amounts of viral RNA. This can be a challenge because the amount of viral RNA not only varies
tremendously between patients, it can also varies within the same patient depending on the
timing of the test and the start of the infection and/or the onset of symptoms. In addition,
nasopharyngeal swabs are not only very unpleasant to the patient, the sampling techniques vary
significantly from nurse to nurse. Without sufficient viral RNA RT-qPCR can return a false
negative test result. RT-qPCR also requires highly trained personnel to perform complex RNA
extraction steps and PCR. Normally, this would not be a problem when testing a few samples.
RT-qPCR becomes an issue when dealing with a global pandemic with potentially thousands of
people to test. This may lead to delays in testing as medical facilities become overloaded.
According to recent studies, false negative results obtained with RT-qPCR are more common
than initially thought. False negative results can have critical impacts on the current efforts to
contain the SARS-CoV-2 outbreak as infected patients are mistakenly given a permission to
return home, return to work and possibly infecting others. Relying solely on nucleic acid tests to
diagnose SARS-CoV-2 may be a risky strategy. As such, needs to add independent testing
methodologies to complement RT-qPCR are becoming increasing important.
IgG/IgM serological tests offer some advantages over RT-qPCR. Firstly, serological tests detect
human antibodies which are known to be much more stable than viral RNA. As a result, IgM/
IgG serological specimens are less sensitive to mistakes during collection, transport, storage and
testing than RT-qPCR specimens. Secondly, because antibodies are typically uniformly
distributed in the blood, serological specimens have much less variations than nasopharyngeal
viral RNA specimens and can be easily collected with minor phlebotomy discomfort to the
patient. Thirdly, unlike RT-qPCR, serological tests can detect past infection because virus-
specific antibodies can persist in the blood for several weeks/months after onset of symptoms.
IgM/IgG serological tests also have some limitations, mainly related to the slow pace of the
human antibody response to SARS-CoV-2. According present knowledge SARS-CoV-2
antibodies may not be detectable before 3 days after onset of symptoms (or at least 7 to 10 days
after infection).
While IgM/IgG serological tests alone may not be enough to diagnose COVID-19, they can be a
valuable diagnostic tool when combined with RT-qPCR. In addition, because of their scalability,
serological assays can be used in large-scale, whole-population, testing to assess the overall
immune response to the virus and identify asymptomatic carriers of the virus. 20-80% of
COVID-19 cases are estimated to be asymptomatic.
How the IgM/IgG Serological Test Results Should be Interpreted
The IgM/IgG serological assay is designed to complement RT-qPCR in the diagnosis of SARS-
CoV-2 infections. Table 1 shows the clinical interpretation of all possible cases that can observed
when testing a patient with both RT-qPCR and an IgM/IgG serological test.
Table 1: Clinical Significance of an IgM/IgG Serological Test Result
This table is based on the current knowledge about the rise and fall of SARS-CoV-2 RNA and
antigens, IgM antibody and IgG antibody and the correlation of these level variations with the
initial time of infection, onset of symptoms and recovery phase. As shown in Figure 1,
serological tests are recommended to be used on patients at least 3 days after onset of symptoms
or 7-10 days after infection with the virus.
The key conclusion is that the RT-qPCR testing may be appropriate for the detection of the
SARS-CoV-2 virus during the acute phase, but IgM/IgG is an appropriate test during the chronic
phase. Since the exact time of infection is often unknown, combining RT-qPCR and IgM/IgG
testing can improve the accuracy of the COVID-19 diagnosis.
Figure 1: Variation of the Levels of SARS-CoV-2 RNA and Antigen, IgM and IgG after infection.
Why Antibody Tests Should Be Used
An antibody test method, or serology test, that detects the presence of SARS-CoV-2 specific
antibodies in the blood has recently received FDA approval in USA. Like the point of care
genome tests, antibody tests are a rapid diagnostic that will give users a verdict within 10 - 15
minutes.
One potential use of antibody tests is to measure the extent of the pandemic at the population or
e.g. at company level. Our understanding of the disease and its projected impact in the
population is weakened by our inability to monitor its spread amongst people with either mild
symptoms or none at all.
Another use is to measure the progress of individual infection. Antibody tests quantify the
number of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies in the blood. The
presence of more IgM antibodies, which are the first to appear and mobilize against an invading
organism, indicates more recent exposure to the virus. It is through this result that an
asymptomatic carrier of the virus could be identified- a feature of no small importance, since
“silent carriers” have played a major role in transmission.
More IgG antibodies, which are virus specific and produced in later stages of infection, would
lead a person to test positive for immunity, implying recovery. This unfortunately doesn’t
guarantee full protection. The test won’t reveal how neutralizing, or how potent, these IgG
antibodies are; nor can it determine how long they will last.
Even with this taken into account, the advantages of antibody tests as a tool against infectious
disease are still numerous—their low cost not least among them. Antibody tests can be
administered for less than $15. The price is but a fraction of the PCR tests. No special assembly
or training is required; Point-of-Care tests could be given flexible in clinics and pharmacies, or
at schools, popup stations, aero ports, railway stations, etc.
Successful deployment of antibody tests, will depend on their “sensitivity and specificity.”
Sensitivity prevents false negatives, since a more sensitive test is more likely to actually detect it.
Specificity, on the other hand, prevents false positives, since a less specific test may pick up on
antibodies against a virus other than SARs-CoV-2. Today Antibody Test kits have sensitivity and
specificity values for IgM and IgG over 97%.
VIVALYTIC
THE ALL IN ONE
MOLECULAR SOLUTION
CONTENTS
1
Vivalytic
& Cartridges
Vivalytic 03
Vivalytic Cartridges 05
Vivalytic Workflow 07
2
Vivalytic
Tests
Respiratory Infections Testing 11
Genitourinary Infections Testing 13
Hospital Acquired Infections Testing 14
3
Vivalytic
Specification
Specifications 19
Vivalytic Up 20
Vivasuite 20
4
Vivalytic
Test Menu
Test Menu 23
01 Vivalytic
& Cartridges
03 Vivalytic & Cartridges
Vivalytic
Vivalytic brings innovation to the Molecular Diagnostic
testing market. It is the result of a collaboration involving
Bosch, the German technology giant, and Randox Laboratories,
a global IVD company. With over 35 years experience in assay
development, Randox is dedicated to improving global healthcare.
Vivalytic enables sample to answer, cartridge-based Molecular
Diagnostic testing. The Vivalytic platform is capable of both
Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR
amplification followed by a suite of detection methods are
combined in a truly revolutionary, fully automated platform.
Manual preparation, cold chain reagents and the use of
multiple devices are no longer required.
No further peripherals such as a laptop, keyboard, barcode
scanner or filling station are required, making Vivalytic a unique
space-saving, hygienic solution for Molecular Diagnostic testing.
Ease of Use Unique Test Menu Fully Automated
Fast Hi-Plex & Lo-Plex Wireless
Test Results Capabilities Connectivity
05 Vivalytic & Cartridges Vivalytic & Cartridges 06
Vivalytic Cartridges Hi-Plex Vivalytic Cartridges
Powered by Randox Biochip Array Technology
Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple
and accurate diagnostic testing. Vivalytic cartridges are powered by a variety of technologies, dependent upon the test application.
Biochip Array Technology enables sample to answer multiplex Molecular Diagnostic testing. Every biochip-powered cartridge
Hi-Plex and Lo-Plex tests can be analysed on the Vivalytic. Hi-Plex tests utilise Randox patented Biochip Array Technology,
produces multiple test results from each patient sample. The intelligent, chemically activated 9x9mm ceramic biochip acts as
enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety
a solid phase reaction surface.
of detection methods including real-time qualitative PCR and melting curve analysis.
The biochips are pre-fabricated with spatially discrete tests regions (DTRs). Each DTR represents an individual test and
each biochip can contain up to 44 DTRs. Each DTR can be occupied with oligonucleotides specific to a pathogen of interest.
The Hi-Plex capabilities of Biochip Array Technology eliminate the need to run multiple time consuming and sample
intensive PCR assays.
The biochip detection system is based on a chemiluminescent signal. This is the emission of light, without heat, due to an
enzymatic chemical reaction. The light emitted from the chemiluminescent reaction that takes place in each DTR is
simultaneously detected and quantified using a Charge - Coupled Device (CCD) Camera. This CCD Camera simultaneously
records the light emission from all the discrete test sites on each biochip. The Vivlaytic automatically generates a result
report for all targets.
All Reagents On-Board
Room Temperature Storage 44 Discrete Testing Regions
Multiplex Technology
9x9mm Biochip
Multiple Sample Types
5 Quality Control Regions
Minimal Contamination Risk
185mm (L) 75mm (W) 17mm (D)
*Actual Size
07 Vivalytic & Cartridges
Vivalytic Workflow
4 Easy Steps for Optimised Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very
simple 4 step workflow. To begin the test, the user scans or enters sample information. The cartridge code is then scanned
into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts
the cartridge into the Vivalytic. The touchscreen display will countdown the time remaining to test completion. Results will
be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one
time all reporting to a master Vivalytic platform.
AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE
1 2
Scan/Input Sample Code Scan/Input Cartridge Code
3 4
Insert Sample into Test Insert Cartridge:
Cartridge and Close Cover Extraction - PCR - Detection
02
Vivalytic
Tests
11 Vivalytic Tests Vivalytic Tests 12
Respiratory
Respiratory Tract Infections (RTI) Chronic Lung Disease (CLD)
The Respiratory Tract Infections is the most comprehensive screening test for infections of both the upper and The Chronic Lung Disease cartridge is a world leading multiplex test, detecting 132 species associated with long term
lower respiratory tracts. It simultaneously detects 14 viral and 8 bacterial infections. The test can be carried out with lung disease e.g. Cystic Fibrosis and Chronic Obstructive Pulmonary Disease (COPD). The 132 species are simultaneously
nasopharyngeal swabs, sputum or broncheoalveolar lavage (BAL). detected across this 32-plex array and includes bacterial, viral, fungal targets and an antibiotic resistance marker from
a single sputum sample. Furthermore, the MecA antibiotic resistance marker is included to assist antibiotic stewardship.
Sample Type: Nasopharyngeal Swab, Sputum, BAL
Sample Volume: 200 μL Sample Type: Sputum
Detection Method: Biochip Array Technology Sample Volume: 200 μL
Detection Method: Biochip Array Technology
VIRUSES
VIRUSES
Influenza A Coronavirus OC43/HKU1 Parainfluenza virus 3
Adenovirus Respiratory syncytial virus B Influenza virus B
Influenza B Enterovirus A/B/C Parainfluenza virus 4
Adenovirus A/B/C/D/E Metapneumovirus Respiratory syncytial virus A/B Metapneumovirus Rhinovirus A/B/C
Bocavirus 1/2/3 Parainfluenza virus 1 Rhinovirus A/B/C Respiratory syncytial virus A Influenza virus A
Coronavirus 229E/NL63 Parainfluenza virus 2 BACTERIA
BACTERIA Achromobacter xylosoxidans Moraxella catarrhalis Pseudomonas aeruginosa
Bordetella pertussis Mycoplasma pneumoniae Staphylococcus aureus
Bordetella parapertussis Haemophilus influenzae Mycoplasma pneumoniae
Burkholderia cepacia complex (21spp) Non-tuberculous mycobacterium (15 spp) Stenotrophomonas maltophilia
Bordetella pertussis Legionella pneumophila Streptococcus pneumoniae
Burkholderia cenocepacia Mycobacterium abscessus subgroup (4 spp) Streptococcus pneumoniae (21 spp)
Chlamydophila pneumoniae Moraxella catarrhalis
Burkholderia multivorans Mycobacterium avium complex (4 spp) Streptococcus species (19 spp)
Chlamydia pneumoniae Pandoraea species (5 spp) Veillonella species (3 spp)
Haemophilus influenza Prevotella species (16 spp)
FUNGI
Flu A/B & RSV
Aspergillus fumigatus Candida albicans Exophialia dermatitidis Scedosporium species (7 spp)
The Flu A/B & RSV assay utilises a one-step real-time PCR format where the automated reverse transcription of influenza
ANTIBIOTIC RESISTANCE MARKERS
RNA and/or RSV RNA is followed by the detection of pathogen specific genes in the same cartridge. The test can be
carried out with nasopharyngeal swabs, sputum or broncheoalveolar lavage (BAL). mecA (incl MRSA)
Sample Type: Nasopharyngeal Swab, Sputum, BAL
Sample Volume: 200 μL
Detection Method: Real-Time PCR
VIRUSES
Influenza A Influenza B Respiratory Syncytial Virus (RSV)
13 Vivalytic Tests Vivalytic Tests 14
Genitourinary Hospital Acquired Infections
Sexually Transmitted Infections (STI) Methicillin-Resistant Staphylococcus Aureus (MRSA)
The Sexually Transmitted Infections is the broadest cartridge-based STI test on the market simultaneously detecting 10 bacterial, MRSA is a qualitative test detecting and differentiating between methicillin-resistant Staphylococcus aureus (MRSA),
viral and protozoan infections for a comprehensive sexual health profile. methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant coagulase-negative Staphylococci (MRCoNS).
A variety of swabs can be used including human nasal or nasal/throat swabs, cultures, wounds, axilla, groin and perineum swabs.
Sample Type: Swab or Urine
Sample Volume: 200 μL Sample Type: Swab
Detection Method: Biochip Array Technology Sample Volume: 200 μL
Detection Method: Real-Time PCR
INFECTIONS
Chlamydia trachomatis (CT) Herpes simplex virus 1 (HSV-1)
BACTERIA
Neisseria gonorrhoea (NG) Herpes simplex virus 2 (HSV-2) Methicillin-resistant Methicillin-sensitive Methicillin-resistant
Staphylococcus aureus (MRSA) Staphylococcus aureus (MSSA) coagulase-negative Staphylococci (MRCoNS)
Trichomonas vaginalis (TV) Haemophilus ducreyi (HD)
Mycoplasma genitalium (MG) Mycoplasma hominis (MH)
Treponema pallidum (Syphilis) (TP) Ureaplasma urealyticum (UU)
Urinary Tract Infections (UTI)
The Urinary Tract Infections is a market leading test detecting bacterial, fungal with associated resistance markers from
a single urine sample. Identification of a multi-plex UTI can prevent further damage to the renal system including the
kidneys and bladder. The various antibiotic resistance markers are included to assist antibiotic stewardship.
Sample Type: Urine
Sample Volume: 200 μL
Detection Method: Biochip Array Technology
BACTERIA
Acinetobacter baumannii Escherichia coli Providencia stuartii
Citrobacter freundii Klebsiella oxytoca Serratia marcescens
Citrobacter koseri Klebsiella pneumoniae Staphylococcus aureus
Klebsiella aerogenes Morganella morganii Staphylococcus epidermidis
Enterobacter cloacae Proteus spp. Staphylococcus saprophyticus
Enterococcus faecalis Pseudomonas aeruginosa Streptococcus agalactiae (GBS)
Enterococcus faecium Providencia rettgeri
FUNGUS
Candida albicans
ANTIBIOTIC RESISTANCE MARKERS
mecA (incl MRSA) Trimethoprim Resistance 4
Trimethoprim Resistance 1 Trimethoprim Resistance 5
Trimethoprim Resistance 2 Van A (Vancomycin Resistance A)
Trimethoprim Resistance 3 Van B (Vancomycin Resistance B)
15 Vivalytic Tests
VIVALYTIC FASCINATES WITH A MARKEDLY
MINIMALIST DESIGN WHOSE STRENGTH
LIES IN ITS HIGH USER-FRIENDLINESS AND
FUNCTIONALITY
03 Vivalytic
Specifications
19 Vivalytic Specifications Vivalytic Specifications 20
Vivalytic Specifications Vivalytic Up
Vivalytic is a versatile analyser suitable as a stand-alone platform. Alternatively, it can be transformed into a modular
and expandable system. Stacking of the analysers provides the user with a scalable, flexible and space saving Molecular
Diagnostic testing solution. Vivalytic Up offers a multi-slot, random access testing platform allowing the user the ability to
use one analyser as the master user-interface that communicates with the other analysers. Integrated cable management
is available allowing just one main power cable to power up to 8 analysers at one time.
400mm
388mm
204mm
PERFORMANCE CHARACTERISTICS Vivasuite
Analyser Type Fully Automated
Sample Volume 200μl All Vivalytic analysers can be connected to Vivasuite, a valuable device management system. Vivasuite is the digital Vivalytic
Relative Humidity Range Operating humidity 30-80% (not condensing) ecosystem allowing you to reduce service cost and ensures clarity of your systems. Vivasuite runs on the Bosch IoT Cloud
Peripherals None Required and applies the highest standards regarding IT security and data privacy. Functionality of the Vivasuite includes registration,
Weight 15KG device management and automatic software updates, giving the device administrators an informed perspective on the usage
Storage Humidity 20-95% (not condensing) of the devices.
Sample Types Sputum, swab, urine, blood and BAL
Storage Capacity 16G Benefits
Noise Output 65 dB
»» Extended warranty options for connected products
POWER & CONNECTIVITY
»» Automatic software updates, including product releases
7" high resolution LCD (RGB)(1024x600)
Display
Touch-sensitive screen (responsive to lab gloves) »» Real-time monitoring of internal machine performance
Electrical Data 100-240 V~, 50/60Hz, 160VA
»» Monitoring of usage in remote settings
SYSTEM CONNECTIONS
Supports: HL7, GDT & POCT-1A
Ethernet 10/100MN
WiFi 2.4GHz (802.11b/g/n)
Data Transfer / Connectivity
Internal: Bluetooth v4.1 2.4 GHz (low energy),
USB 2.0, 3 USB Ports
GSM
Memory Capacity 16GB
04Vivalytic
Test Menu
23 Vivalytic Test Menu 24
Test Menu
TEST TARGETS
RESPIRATORY
14 viral targets
Respiratory Tract Infection Array
8 bacterial targets
Flu A/Flu B/RSV 3 viral targets
20 bacterial targets
7 viral targets
Chronic Lung Infection Array
4 fungal targets
1 antibiotic resistance marker
GENITOURINARY
Sexually Transmitted Infection Array 10 targets
20 bacterial targets
Urinary Tract Infection Array 1 fungal targets
8 antibiotic resistance markers
HOSPITAL ACQUIRED INFECTIONS
MRSA 3 bacterial targets
Molecular Quality Solutions
Randox has a strategic partnership with both Qnostics and QCMD, internationally renowned providers of IQC and
EQA products for infectious diseases. Qnostics are a provider of complete QC solutions and their products can be used in
the daily monitoring of assay performance. Linearity assessment, assay evaluation, validation/verification of new assays
and staff training can also be facilitated using these products.
QCMD also play an essential role in assuring laboratory quality by providing EQA samples across a wide range of
infectious disease areas.
For more information email
[email protected]
55 Diamond Road,
Crumlin,
Co. Antrim,
United Kingdom,
BT29 4QY
Email.
[email protected]
Tel. +44 (0) 28 9442 2413
randoxbiosciences.com
LT735MAR19
Information correct at time of print.
Randox Laboratories Limited is a subsidiary of Randox Holdings Limited a company registered within
Northern Ireland with company number N.I. 614690. VAT Registered Number: GB 151 6827 08.
Product availability may vary from country to country. Please contact your local Randox representative for information.
Products may be for Research Use Only and not for use in diagnostic procedures in the USA.